Physician profile
Casey H Cox
NPI 1952662447
$2,134.66
in general payments reported to CMS, 2019-2025
27 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2023: $15.58 · 2024: $1,251 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $508.50 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $233.29 | 2023-2025 | |
| Novo Nordisk INC | $199.94 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $188.76 | 2024 | Breztri, Farxiga, Fasenra |
| Exact Sciences Corporation | $151.38 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.05 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $98.09 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $71.07 | 2024-2025 | Veozah |
| Dexcom, INC. | $63.57 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $60.81 | 2021-2025 | |
| Edwards Lifesciences Corporation | $42.75 | 2024-2025 | |
| Saluda Medical Americas, INC. | $41.96 | 2025 | Evoke |
| Sumitomo Pharma America, INC. | $41.83 | 2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $40.82 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.62 | 2024 | Ofev, Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.90 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $27.77 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $23.86 | 2021 | |
| Corcept Therapeutics | $19.03 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $18.81 | 2021 | |
| Inspire Medical Systems, INC. | $17.23 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $16.56 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.23 | 2024 | Rexulti |
| Almatica Pharma LLC | $14.45 | 2024 | Teriparatide |
| Amgen INC. | $13.89 | 2025 | Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $13.83 | 2024 | Unithroid |
| Vertex Pharmaceuticals Incorporated | $13.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.